Drug Approvals, Financial Results, Market Activity, New Mobile Applications, and Company Updates - Research Reports on Intercept, Exact Sciences, Thermo Fisher Scientific, Illumina and Agilent

NEW YORK, August 15, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Intercept Pharmaceuticals, Inc. (NASDQ: ICPT), Exact Sciences Corporation (NASDAQ: EXAS), Thermo Fisher Scientific, Inc. (NYSE: TMO), Illumina Inc. (NASDAQ: ILMN) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5768-100free.

--
Intercept Pharmaceuticals, Inc. Research Reports
On August 12, 2014, shares of Intercept Pharmaceuticals, Inc. (Intercept) rallied 16.59% from its previous day's close, on record high trading volumes, to end the trading session at $276.52. As per a news report on Fox Business, the stock market reacted positively after the Company said that it's most advanced candidate performed better than a placebo in a mid-stage study of patients with a form of chronic liver disease. Intercept now plans to start late-stage clinical testing in H1 2015 for obeticholic acid, or OCA, as a possible treatment for nonalcoholic steatohepatitis, or NASH. A day before, the Company reported Q2 2014 net income of $33.5 million, compared to a net loss of $13.5 million for Q2 2013. As per the Company, the Q2 2014 net income was bloated by a $55.8 million non-cash gain recorded for the revaluation of all outstanding warrants which were exercised in April 2014. The full research reports on Intercept are available to download free of charge at:

http://www.analystsreview.com/Aug-15-2014/ICPT/report.pdf

--
Exact Sciences Corporation Research Reports
On August 12, 2014, Exact Sciences Corporation (Exact Sciences) said that U.S. Food and Drug Administration (FDA) has approved Cologuard - the Company's noninvasive, stool DNA colorectal cancer screening test. As per the Company, the approved product is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92% of cancers and 69% of the most advanced precancerous polyps in average risk patients. According to the Company, the drug offers people aged 50 and above, at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home. Reacting to the news, shares rose as much as 12.05%, the same day, to finally settle at $17.46, up 2.17%. A significant volume of shares (14.60 million) were traded during the day. The full research reports on Exact Sciences are available to download free of charge at:

http://www.analystsreview.com/Aug-15-2014/EXAS/report.pdf

--
Thermo Fisher Scientific, Inc. Research Reports
On August 6, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher Scientific) announced the launch of a new mobile application - ChemSearch, which enables chemists to access chemical structures and compounds required for daily work. The new app features the intuitive mobile chemical drawing technology, ChemDoodle from iChemLabs, designed to enable scientists to easily draw and search chemical structures to identify the right chemicals and compounds required for their work. The app is available for Apple iPhone and iPad devices. The full research reports on Thermo Fisher Scientific are available to download free of charge at:

http://www.analystsreview.com/Aug-15-2014/TMO/report.pdf

--
Illumina Inc. Research Reports
On August 12, 2014, shares of Illumina Inc. (Illumina) fell 0.74% from its previous day's close to end the trading session at $162.92. The stock opened at $165.34, touched an intraday high of $166.27 and a low of $161.90. A total of 0.89 million shares were traded, lower than 30-day average trading volume of 1.27 million shares. The stock has a 52-week low of $72.77 and a 52-week high of $185.00. Over the past 12-months, the stock has rallied 106.99%, significantly outperforming the NASDAQ Composite, which returned 19.92% during the same time period. The full research reports on Illumina are available to download free of charge at:

http://www.analystsreview.com/Aug-15-2014/ILMN/report.pdf

--
Agilent Technologies Inc. Research Reports
On August 1, 2014, the electronic measurement business of Agilent Technologies Inc. (Agilent) - Keysight Technologies, Inc. announced that it has begun operating under the Keysight name. According to Agilent, Keysight will remain a wholly owned subsidiary of the Company until early November this year, when the separation is expected to be completed and Keysight begins trading on the NYSE under the symbol KEYS. On September 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. As a result of the separation of businesses, sciences, diagnostics and applied markets (LDA) will be under Agilent. The full research reports on Agilent are available to download free of charge at:

http://www.analystsreview.com/Aug-15-2014/A/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review